Profound Medical Corp.

Profound Medical Corp. announced the launch of 'Let's Huddle', a global patient advocacy initiative designed to empower men and their families throughout their prostate care journey. The program, led by former NFL player and prostate cancer survivor Leonard Wheeler, focuses on providing education, connection, and support. This initiative underscores Profound's commitment to patient-centered care, extending beyond its medical device technology to foster informed decision-making and community support.

Profound Medical Corp. announced the launch of 'Let's Huddle,' a global patient community designed to empower men and their families throughout the prostate care journey. Led by Global Patient Ambassador Leonard Wheeler, the initiative aims to provide education, peer support, and advocacy. This program reflects Profound's commitment to patient-centered care, extending beyond its TULSA-PRO® technology to support individuals from diagnosis through survivorship.

Profound Medical Corp. reported a 12.3% increase in Q2 2026 revenue to $2.48 million, with net loss narrowing by 39.3% to $9.54 million. For the first six months of 2026, revenue surged by 61.8% to $7.82 million, and net loss decreased by 37.2% to $16.59 million. The company, a foreign private issuer, voluntarily filed this 10-Q, highlighting its TULSA-PRO system and Sonalleve platform.

Profound Medical reported Q2 2026 revenue of $2.5 million, a 12% year-over-year increase, with a net loss of $9.5 million, a 39% improvement. The company noted that $3.1 million in TULSA product shipments were delayed to Q3, which would have boosted Q2 revenue to $5.6 million, representing 153% year-over-year growth. Profound reiterated its full-year 2026 revenue guidance of approximately $25.0 million and announced new employer health plans covering the TULSA Procedure, further expanding payer coverage.

Profound Medical Corp. announced new data from its Level 1 post-market CAPTAIN randomized controlled trial, comparing the TULSA Procedure with robotic radical prostatectomy for prostate cancer. The TULSA Procedure demonstrated statistically significant superiority in preserving penile length, showing no median change at one month compared to a 0.65 cm reduction with robotic RP. These findings add to previously announced results where TULSA showed superior preservation of erectile function and urinary continence.

Profound Medical Corp. announced new data from its Level 1 post-market CAPTAIN randomized controlled trial, comparing the TULSA Procedure with robotic radical prostatectomy for intermediate-risk prostate cancer. The TULSA Procedure showed no median change in penile length at 1 month, significantly outperforming robotic RP which resulted in a median 0.65 cm reduction. This new data, presented at the Society of Robotic Surgery Annual Meeting, builds on previous findings that demonstrated TULSA's superiority in preserving erectile function and urinary continence.

Profound Medical Corp. announced that it will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Following the release, the company will host a conference call at 4:30 p.m. Eastern Time on the same day to review the financial results and discuss business developments.

Profound Medical Corp. announced that its TULSA Procedure™ will be prominently featured in several presentations by leading physicians at the upcoming Society of Robotic Surgery (SRS) Annual Meeting. The presentations will cover various clinical outcomes and applications of the MRI-guided, AI-powered prostate ablation technology. Additionally, Profound was selected as one of eight companies to be spotlighted during the Society of Incisionless Surgery (SIS) plenary session, and its management will participate in an investor session at the conference.

Profound Medical Corp. held its 2026 Annual General and Special Meeting of Shareholders on May 13, 2026. Shareholders elected eight director nominees to the Board, approved the appointment of PricewaterhouseCoopers LLP as auditors, and passed an ordinary resolution to approve all unallocated restricted share units and deferred share units under the company's long-term incentive plan. All proposals presented at the meeting were approved by the security holders.

Profound Medical Corp. announced that its TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association's Annual Meeting on May 16, 2026. The company also revealed an initiative to explore integrating PSMA PET molecular imaging technologies with the TULSA Procedure to enhance treatment planning and patient monitoring for prostate ablation. This development aims to empower physicians with greater precision and confidence in delivering tailored treatments.